Publication: PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future †
| dc.contributor.author | Gokengin, Deniz (6603234930) | |
| dc.contributor.author | Bursa, Dominik (57194389543) | |
| dc.contributor.author | Skrzat-Klapaczynska, Agata (57200220975) | |
| dc.contributor.author | Alexiev, Ivailo (24400977400) | |
| dc.contributor.author | Arsikj, Elena (58078722500) | |
| dc.contributor.author | Balayan, Tatevik (56049390500) | |
| dc.contributor.author | Begovac, Josip (7004168039) | |
| dc.contributor.author | Cicic, Alma (57191286606) | |
| dc.contributor.author | Dragovic, Gordana (23396934400) | |
| dc.contributor.author | Harxhi, Arjan (8690048500) | |
| dc.contributor.author | Aimla, Kerstin (57908888600) | |
| dc.contributor.author | Lakatos, Botond (36614563800) | |
| dc.contributor.author | Matulionyte, Raimonda (12239067500) | |
| dc.contributor.author | Mulabdic, Velida (30067838900) | |
| dc.contributor.author | Oprea, Cristiana (21636591500) | |
| dc.contributor.author | Papadopoulos, Antonios (7101944704) | |
| dc.contributor.author | Rukhadze, Nino (54883291900) | |
| dc.contributor.author | Sedlacek, Dalibor (57202125317) | |
| dc.contributor.author | Sojak, Lubomir (57218826535) | |
| dc.contributor.author | Tomazic, Janez (6603749556) | |
| dc.date.accessioned | 2025-07-02T11:57:54Z | |
| dc.date.available | 2025-07-02T11:57:54Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1–80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region. © 2023 by the authors. | |
| dc.identifier.uri | https://doi.org/10.3390/vaccines11010122 | |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85146911661&doi=10.3390%2fvaccines11010122&partnerID=40&md5=5aa434e35fcb12bd851070eac6648895 | |
| dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/11965 | |
| dc.subject | Central and Eastern Europe | |
| dc.subject | HIV | |
| dc.subject | post-exposure prophylaxis | |
| dc.subject | pre-exposure prophylaxis | |
| dc.title | PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future † | |
| dspace.entity.type | Publication | |
